Short Interest in XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Grows By 286.4%

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 36,172 shares, an increase of 286.4% from the June 30th total of 9,362 shares. Based on an average daily trading volume, of 57,229 shares, the days-to-cover ratio is currently 0.6 days. Currently, 2.3% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, XTL Biopharmaceuticals currently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Up 1.4%

Shares of XTL Biopharmaceuticals stock traded up $0.04 during trading on Friday, reaching $2.94. 1,415 shares of the company were exchanged, compared to its average volume of 200,273. The business has a 50-day moving average price of $2.59 and a 200-day moving average price of $2.87. The firm has a market capitalization of $6.47 million, a price-to-earnings ratio of -4.59 and a beta of 1.45. XTL Biopharmaceuticals has a twelve month low of $2.01 and a twelve month high of $10.28.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of ($0.26) million during the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.